Brief: Oncolytics Biotech Partner Adlai Nortye Doses First Patient In Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel
14/10/2021 12:59
Oct 14 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH®PARTNER ADLAI NORTYE DOSES FIRST
PATIENT IN
CHINESE BRIDGING TRIAL EVALUATING PELAREOREP-PACLITAXEL
COMBINATION TREATMENT IN BREAST CANCER
Source text for Eikon: ID:nCNWYlwKLa
Further company coverage: ONC.TO
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Files For Mixed Shelf Offering Of Up To $150 Million
Brief: Oncolytics Biotech® Announces Voluntary Delisting From The Toronto Stock Exchange
Advisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
Brief: Oncolytics Biotech® Appoints Former Ambrx Executive As Chief Business Officer
Brief: Oncolytics Biotech Appoints Former Ambrx Executive As Chief Business Officer